69,756 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by Deutsche Bank AG

Deutsche Bank AG bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 69,756 shares of the company's stock, valued at approximately $6,800,000. Deutsche Bank AG owned approximately 0.13% of Dianthus Therapeutics as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of DNTH. Wellington Management Group LLP grew its holdings in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock worth $101,431,000 after purchasing an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP raised its holdings in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after buying an additional 1,499,931 shares during the last quarter. State Street Corp raised its holdings in Dianthus Therapeutics by 124.7% in the 4th quarter. State Street Corp now owns 1,507,619 shares of the company's stock valued at $62,129,000 after buying an additional 836,571 shares during the last quarter. Polar Capital Holdings Plc bought a new position in Dianthus Therapeutics in the 3rd quarter valued at approximately $29,434,000. Finally, Marshall Wace LLP acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $22,545,000. 47.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares of the company's stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Anne Mcgeorge sold 7,750 shares of Dianthus Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the transaction, the director directly owned 1,250 shares of the company's stock, valued at approximately $136,262.50. This trade represents a 86.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 287,084 shares of company stock valued at $29,615,923 over the last quarter. Company insiders own 3.02% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on DNTH. Truist Financial upped their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. TD Cowen reiterated a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim restated a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Raymond James Financial restated a "strong-buy" rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $124.27.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $110.07 on Tuesday. The firm has a market cap of $6.02 billion, a price-to-earnings ratio of -26.52 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 52-week low of $22.81 and a 52-week high of $117.88. The firm has a 50 day moving average price of $101.30 and a two-hundred day moving average price of $85.62.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source